News & Moves: SKBI, CLDX, ABGB, FOLD

(RTTNews) - Skystar Looking Up...

Skystar Bio-Pharmaceutical Co. (SKBI) delivered yet another strong quarterly performance with an eye on long term goals to improve key performance metrics including top line growth, gross margins and bottom line profitability.

In the third-quarter ended September 30, 2014, net income rose to $4.9 million or $0.57 per share on revenue of $18.4 million. This compares with a net income of $3.7 million or $0.49 per share and revenue of $15.99 million in the year ago period.

For full year 2014, the company continues to expect revenue in the range of $46 million to $50 million. Revenue was $42.5 million in 2013.

Skystar noted that it is in mid-transition to large scale manufacturing of its animal vaccine and medicine products at one of its modern GMP production facilities.

CLDX ReACTs Positively

Celldex Therapeutics Inc.'s (CLDX) phase II study of its drug candidate Rindopepimut in recurrent Bevacizumab(Avastin)-naive glioblastoma patients, dubbed ReACT, has demonstrated statistically significant survival benefit.

The ReACT study is designed to determine if adding Rindopepimut to standard of care Bevacizumab improves the outcomes for patients with EGFRvIII-positive recurrent glioblastoma across multiple measures.

CLDX is up more than 13% to $16 in Monday's premarket trading.

ABGB Getting Renewed?

Abengoa S.A. (ABGB) is up more than 25% to $11.32 in pre-market trading Monday as the Spanish renewable energy and engineering firm spelt out its action plan related to its business, Green Bond, non recourse debt and cash position on a call with investors and analysts this morning.

ABGB had slipped to an all-time low of $7.71 on November 14, 2014 on net debt concerns and guarantees provided under one of its high yield bonds.

What's Unfolding In Fold?

Shares of Amicus Therapeutics (FOLD) are up more than 13% to $6.47 in pre-market trading Monday, following additional positive data on secondary endpoints from its second phase III study of Migalastat HCl for Fabry disease.

In the phase III trial, dubbed Study 012, there was statistically significant improvement in key cardiac parameter in patients switched from enzyme replacement therapies to Migalastat HCL.

The company said it is on track to hold pre-submission meeting with European regulators this quarter, and expect to interact with the FDA in early 2015.